Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
|
Relief Therapeutics Holding SA / Key word(s): Annual Results Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update GENEVA (APR. 10, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today published its 2024 Annual Report and provided a corporate update. In his annual letter to shareholders, Dr. Raghuram Selvaraju, chairman of the board of directors, emphasized the Company’s operational achievements, pipeline momentum, and strengthened financial position. “This past year, we built a stronger foundation and made measurable progress in executing our plans as we advanced our core pipeline and optimized our commercial strategy, always guided by our commitment to delivering meaningful solutions for patients with unmet medical needs,” said Dr. Selvaraju. “We are particularly excited by the continued progress of RLF-OD032, our next-generation liquid sapropterin formulation for phenylketonuria, and RLF-TD011, our proprietary hypochlorous acid solution for epidermolysis bullosa. We look forward to important clinical and regulatory milestones in 2025.” Relief’s 2024 Annual Report, which includes pipeline and portfolio updates, corporate governance and compensation disclosures, and financial statements, is available on the Company’s website. ABOUT RELIEF CONTACT DISCLAIMER Additional features: File: Ad hoc End of Inside Information |
| Language: | English |
| Company: | Relief Therapeutics Holding SA |
| Avenue de Secheron 15 | |
| 1202 Geneva | |
| Switzerland | |
| Phone: | +41 22 545 11 16 |
| E-mail: | contact@relieftherapeutics.com |
| Internet: | https://relieftherapeutics.com |
| ISIN: | CH1251125998 |
| Valor: | 125112599 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 2114490 |
| End of Announcement | EQS News Service |
|
|
2114490 10-Apr-2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.